跳至主要内容
临床试验/NL-OMON41461
NL-OMON41461已完成3 期

CONgenital Cytomegalovirus: Efficacy of antiviral treatment in a non-Randomized Trial with historical control group - CONCERT study 2.0

eids Universitair Medisch Centrum0 个研究点目标入组 50 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
2 至 11(—)

入选标准

  • Treatment group and refusal control group
  • - Infants with congenital CMV infection, and hearing loss (* 20 dB, in one or both ears).
  • - Age at time of inclusion is * 12 weeks after birth.
  • - Born at * 37 weeks gestational age.
  • - Birth weight > -2 SD corrected for duration of pregnancy and ethnic origin.
  • - Parental signed informed consent.;Historical control group
  • - Infants with congenital CMV infection, and hearing loss (* 20 dB, in one or both ears).
  • - Age at time of inclusion is > 13 weeks after birth.
  • - Born at * 37 weeks gestational age.
  • - Birth weight > -2 SD corrected for duration of pregnancy and ethnic origin.
  • - Parental signed informed consent.

排除标准

  • Treatment group and refusal control group
  • - Previously noted (* 12 weeks after birth) symptoms possibly related to congenital CMV, for which medical attention was requested. For
  • example: intra uterine growth retardation, petechiae, hepatosplenomegaly, jaundice, microcephaly, thrombocytopenia, elevated transaminases, elevated bilirubin.
  • - Treatment with other antiviral agents or immunoglobulins.
  • - Solely applicable for treatment group: leucopenia < 0,5 x 10*9/L (blood sample tested at t=0).;Historical control group
  • - Previously encountered (* 12 weeks after birth) symptoms possibly related to congenital CMV, for which medical attention was requested For example: intra uterine growth retardation, petechiae, hepatosplenomegaly, jaundice, microcephaly, thrombocytopenia, elevated transaminases, elevated bilirubin.
  • - Treatment with (val)ganciclovir.
  • - Treatment with other antiviral agents or immunoglobulins.

研究者

相似试验

进行中(未招募)
1 期
Efficacy of antiviral treatment of congenital cytomegalovirus in a non-randomized trial with historical control groupCongenital cytomegalovirus infection.Sensorineural Hearingloss.MedDRA version: 18.0Level: LLTClassification code 10010420Term: Congenital CMV infectionSystem Organ Class: 100000004850
EUCTR2013-003068-30-NLMC50
进行中(未招募)
不适用
Efficacy of antiviral treatment of congenital cytomegalovirus in a randomized controlled trialCongenital cytomegalovirus infection.Sensorineural Hearingloss.MedDRA version: 14.1Level: LLTClassification code 10010420Term: Congenital CMV infectionSystem Organ Class: 10010331 - Congenital, familial and genetic disorders
EUCTR2011-005378-44-NLMC
进行中(未招募)
不适用
Efficacy and safety of anti-cytomegalovirus prophylaxis versus pre-emptive approaches with valganciclovir in heart transplant recipients treated with everolimus or mycophenolate. A randomized open-label study for prevention of cardiac allograft vasculopathy - PROTECTHeart transplantationMedDRA version: 9.1Level: LLTClassification code 10019315Term: Heart transplant rejection
EUCTR2008-006980-35-ITAZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
进行中(未招募)
1 期
Traitement prénatal de l'infection congénitale à cytomégalovirus par le letermovir randomisé contre le valaciclovirStep 1: Maternal administration of 1 tablet of Letermovir (240 mg or 480 mg /day) during 3 days before TOPStep 2: Maternal daily administration of 240 or 480 milligrams of letermovir (1x240 mg-tablets) or (1x480 mg-tablets) (the dose will be choosen depending on the results obtained on step 1) up-until delivery or TOP
EUCTR2020-002924-35-FRASSISTANCE PUBLIQUE HÔPITAUX DE PARIS56
进行中(未招募)
1 期
Impact of anti-cytomegalovirus (valganciclovir) treatment in the management of relapsing ulcerative colitis (UC) requiring vedolizumab therapy: a randomized clinical trial comparing a strategy with or without antiviral therapyPatient with active ulcerative colitis who failed to anti-TNF with endoscopic active disease with an endoscopic Mayo score> 1 and 2 biopsies of the inflammatory tissue and presence of a CMV infection in the inflammatory tissue objectified by a viral load greater than 5 IU / 100000 cells by qPCR.MedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856MedDRA version: 20.1Level: LLTClassification code 10058881Term: Cytomegalovirus viremiaSystem Organ Class: 100000004862
EUCTR2019-001032-54-FRCHU de Saint Etienne120